A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE 3 STUDY OF GEMCITABINE-CISPLATIN CHEMOTHERAPY PLUS NECITUMUMAB (IMC-11F8) VERSUS GEMCITABINE-CISPLATIN CHEMOTHERAPY ALONE IN THE FIRST- LINE TREATMENT OF PATIENTS WITH STAGE IV SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)

Trial Profile

A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE 3 STUDY OF GEMCITABINE-CISPLATIN CHEMOTHERAPY PLUS NECITUMUMAB (IMC-11F8) VERSUS GEMCITABINE-CISPLATIN CHEMOTHERAPY ALONE IN THE FIRST- LINE TREATMENT OF PATIENTS WITH STAGE IV SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Nov 2017

At a glance

  • Drugs Necitumumab (Primary) ; Cisplatin; Gemcitabine
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms SQUIRE
  • Sponsors Eli Lilly; ImClone Systems
  • Most Recent Events

    • 17 Nov 2017 Results of an analysis assessing correlation of granular EGFR-FISH parameters with clinical outcomes of necitumumab, published in the Journal of Thoracic Oncology.
    • 01 Jun 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
    • 15 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top